E-LIB Suche - Ergebnisse für: Nahi, Hareth

1

In multiple myeloma, monthly treatment with zoledronic acid..:

Lund, Thomas ; Gundesen, Michael Tveden ; Juul Vangsted, Annette...
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

2

Effectiveness and infectious complications of BCMA T‐cell e..:

Uttervall, Katarina ; Tätting, Love ; Lemonakis, Konstantinos...
Cancer Medicine. 13 (2024) 8 - p. , 2024

Link: https://doi.org/10.1002/..

3

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment w..:

Partanen, Anu ; Waage, Anders ; Peceliunas, Valdas...
Cancers. 16 (2024) 5 - p. 1024 , 2024

Link: https://doi.org/10.3390/..

4

P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLE..:

Gundesen, Michael ; Schjesvold, Fredrik ; Vangsted, Annette...
HemaSphere. 7 (2023) S3 - p. e014785b , 2023

Link: https://doi.org/10.1097/..

5

Corticosteroid tapering is a safe approach in patients with..:

Nahi, Hareth ; Usmani, Saad Z. ; Mateos, Maria-Victoria...
Leukemia & Lymphoma. 64 (2023) 2 - p. 468-472 , 2023

Link: https://doi.org/10.1080/..

6

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUA..:

Silvennoinen, Raija ; Partanen, Anu ; Waage, Anders...
HemaSphere. 7 (2023) S3 - p. e5534069 , 2023

Link: https://doi.org/10.1097/..

7

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLI..:

Bhutani, Manisha ; Garfall, Alfred ; Uttervall, Katarina...
HemaSphere. 7 (2023) S3 - p. e90600b0 , 2023

Link: https://doi.org/10.1097/..

8

Plain Language Summary of the MAIA Study of Daratumumab Plu..:

Facon, Thierry ; Kumar, Shaji K ; Plesner, Torben...
Future Oncology. 19 (2023) 13 - p. 887-895 , 2023

Link: https://doi.org/10.2217/..

9

Potential value of pre-planned imaging of bone disease in m..:

Gundesen, Michael T. ; Asmussen, Jon Thor ; Schjesvold, Fredrik...
Blood Cancer Journal. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

10

OA-10 Four years treatment with zoledronic acid is superior..:

Gundesen, Michael ; Schjesvold, Fredrik ; Vangsted, Annette Juul...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S6-S7 , 2023

Link: https://doi.org/10.1016/..

11

POSTER: MM-162 Durability of Responses With Biweekly Dosing..:

Usmani, Saad Z ; Karlin, Lionel ; Benboubker, Lotfi...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S224 , 2023

Link: https://doi.org/10.1016/..

12

Plain language summary of the MajesTEC-1 study of teclistam..:

Moreau, Philippe ; van de Donk, Niels WCJ ; Nahi, Hareth...
Future Oncology. 19 (2023) 12 - p. 811-818 , 2023

Link: https://doi.org/10.2217/..

13

Minimal residual disease status is the prognostic determina..:

Nahi, Hareth ; Afram, Gabriel ; Uttervall, Katarina...
Cancer Medicine. 12 (2023) 22 - p. 20736-20744 , 2023

Link: https://doi.org/10.1002/..

14

MM-162 Durability of Responses With Biweekly Dosing of Tecl..:

Usmani, Saad Z ; Karlin, Lionel ; Benboubker, Lotfi...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S477 , 2023

Link: https://doi.org/10.1016/..

15

Generation of NK cells with chimeric-switch receptors to ov..:

Susek, Katharina H. ; Schwietzer, Ysabel A. ; Karvouni, Maria...
Cancer Immunology, Immunotherapy. 72 (2022) 5 - p. 1153-1167 , 2022

Link: https://doi.org/10.1007/..